newsfilter
← Latest News
GlobeNewswire·

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

  • BioCryst granted an Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe.
  • BioCryst will receive a $70M upfront payment, up to $275M in future regulatory & sales milestone payments, & tiered royalties on net sales ranging from 18% to 30%.
  • The agreement builds upon a prior arrangement for Neopharmed Gentili to acquire the European ORLADEYO business in 2025.
  • Navenibart is an investigational, long-acting plasma kallikrein inhibitor with a Phase 3 program on track for US regulatory filing by end of 2027.
  • The partnership aims to optimize commercial focus by having dedicated US & European organizations lead product launches in their respective territories.
  • The transaction provides near-term capital to strengthen BioCryst's balance sheet while retaining potential upside through milestones & royalties.
  • Neopharmed Gentili will utilize its existing European commercial infrastructure originally built by BioCryst for ORLADEYO to ensure execution continuity.